CD Capital’s portfolio company Jenscare was successfully listed on the Main Board of the Hong Kong Stock Exchange

On October 10, 2022, Ningbo Jenscare Scientific Co., Ltd. (hereinafter referred to as "Jenscare," stock code: 9877.HK), a portfolio company of CD Capital, successfully listed on the Main Board of the Hong Kong Stock Exchange.

As the earliest institutional investor in Jenscare, CD Capital invested in the company in April 2018 and made two additional investments in 2020, deeply participating in Jenscare’s development.

Structural heart disease refers to a group of diseases caused by acquired or congenital abnormalities in large blood vessels or heart structures. Globally, the market penetration of treatments for structural heart disease remains low due to a lack of effective therapeutic options. Jenscare is dedicated to developing interventional products for the treatment of structural heart diseases and has already developed a series of treatment solutions for various types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases, and heart failure.

Among the manufacturers with clinical approval for tricuspid valve replacement devices, one set of data shows that in 2021, there were 51.7 million moderate to severe tricuspid regurgitation patients worldwide, including 9.3 million in China. By 2030, these numbers are expected to increase to 60.7 million globally and 10.6 million in China. Patients with tricuspid regurgitation typically face low quality of life and high mortality, creating a strong demand for treatment.

Jenscare's core product, LuX-Valve (Transcatheter Tricuspid Valve Replacement System), has the potential to treat severe tricuspid regurgitation and is the world’s first investigational product to complete enrollment in a confirmatory clinical trial. In November 2021, this product was designated as a "Breakthrough Device" under the U.S. FDA’s Breakthrough Devices Program, making it the first domestically developed medical device in the field of heart valve disease to receive such recognition.

In addition to LuX-Valve, Jenscare is also developing two other transcatheter tricuspid valve intervention devices: LuX-Valve Plus and JensT-Clip. LuX-Valve Plus is expected to receive approval from the National Medical Products Administration (NMPA) in the first half of 2024 and enter commercial production. Furthermore, LuX-Valve Plus has successfully completed implantation procedures for 11 trial subjects in Canada and has also seen successful implantations in the United States, France, and Germany.

Leveraging its technical strength in tricuspid valve disease, Jenscare has developed an extensive product pipeline for other structural heart diseases, including aortic valve diseases, mitral valve diseases, and heart failure.

Currently, Jenscare has developed two transcatheter aortic valve replacement (TAVR) products to treat severe aortic regurgitation (or aortic stenosis combined with aortic regurgitation). Another core product, Ken-Valve (Transcatheter Aortic Valve Replacement System), is expected to receive NMPA approval in the first half of 2024 and be commercialized. In addition, a new-generation TAVR product, KenFlex, is expected to be commercialized in the first half of 2025.

Among other investigational products for treating mitral valve diseases and heart failure, Jenscare’s independently developed transcatheter mitral valve repair clip system, JensClip, has also entered the feasibility clinical trial stage.

Jenscare has built a comprehensive platform capable of turning strategic concepts into real investigational products. The company has established full-cycle R&D capabilities, from identifying medical needs to product development and commercialization. It has set up a simulation lab that integrates computer-aided engineering analysis and valve testing, allowing for in vitro experiments during the process development stage to analyze the mechanisms of investigational products.

Jenscare also has complete manufacturing capabilities, including production lines for stents, valves, and delivery systems, with an annual production capacity of 4,000 to 5,000 units, which it expects to expand further.

Looking ahead, Jenscare is committed to becoming a global leader in medical devices. The company will continue accelerating the development and commercialization of its investigational products while deepening and expanding its broad, diverse, and strong pipeline for heart valve disease and heart failure products.